Epidermodysplasia verruciformis: a rare case presentation
DOI:
https://doi.org/10.66344/jpad.v27i1.1037Keywords:
Epidermodysplasia verruciformis, human papilloma virusAbstract
Epidermodysplasia verruciformis (EV) is a rare genodermatosis characterized by a unique susceptibility to cutaneous infection by a group of phylogenetically related human papilloma viruses (HPVs). These patients show a defect in cell-mediated immunity specific toward the causative HPVs that leads to lifelong disease. The defect is usually inherited as autosomal recessive trait and presents clinically with plane warts, pityriasis versicolor-like lesions and reddish verrucous plaques. Dysplastic and malignant changes in the form of actinic keratoses, Bowen's disease and squamous cell carcinoma (SCC) are common but metastasis occurs rarely. A totally effective treatment against EV is as yet highly desirable. We report a case of EDV in a 13-year-old female patient with confluent wart like lesions, pityriasis versicolor like lesions and reddish plaques. The case is being reported in view of rarity of disease.
References
Daudιn E, Fraga J, Garcνa-Dνez A. Epidermodysplasia verruciformis-like lesions in a patient with systemic lupus erythematosus. Acta Derm Venereol. 2003;83:229-30.
2. Ostrow RS, Manias D, Mitchell AJ, Stawowy L, Faras AJ. Epidermodysplasia verruciformis. A case with primary lymphatic dysplasia, depressed cell-mediated immunity, and Bowen's disease containing human papilloma 16 DNA. Arch Dermatol. 1987;123:1511-6.
3. Pfister H. Human papilloma viruses and impaired immunity vs epidermodysplasia verruciformis. Arch Dermatol. 1987;123:1469-70.
4. Anadolu R, Oskay T, Erdem C, Boyvat A, Terzi E, Gürgey E. Treatment of epidermodysplasia verruciformis with a combination of acitretin and interferon alfa-2a. J Am Acad Dermatol. 2001;45:296-9.
5. Rallis E, Paparizos V, Kyriakis K, Katsambas A. Treatment of epidermodysplasia verruciformis in human immunodeficiency virus-positive patients. J Eur Acad Dermatol Venereol. 2009;23:195-6.
6. Hayashi J, Matsui C, Mitsuishi T et al. Treatment of localized epidermodysplasia verruciformis with tacalcitol ointment. Int J Dermatol. 2002;41:817-20.
7. Berthelot C, Dickerson MC, Rady P, He Q, Niroomand F, Tyring SK et al. Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. J Am Acad Dermatol. 2007;56:882-6.
8. Ishiji T, Ibe M, Kawase M, Niimura M. Patients with epidermodysplasia verruciformis show no response to contact immunotherapy. Dermatology. 2001;202:76-7.
9. Micali G, Nasca MR, Dall’Oglio F, Musumeci ML. Cimetidine therapy for epidermodysplasia verruciformis. J Am Acad Dermatol. 2003;48:S9-10.
10. de Oliveira WR, Neto CF, Rivitti EA. The lack of a clinical effect of cimetidine in the treatment of epidermodysplasia verruciformis. J Am Acad Dermatol. 2004;50:e14.
Downloads
Published
Issue
Section
License
Copyright (c) 2017 Kumar Prateek, Shyam Sundar Chaudhary, Sonal Sachan, Yuvraj Sahu, Pooja Choubey
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
